- Solid Q2 EBITDA beat driven by both better growth and lower costs - We lift '24e-'26e EBITDA 4-5% ...
- Medicare expands lower-limb prosthetics coverage from 1 Sep - Good news for patients and Embla Med...
- EBITA SEK 245m (0% vs. ABGSCe, +2% vs. Modular Finance IR cons) - Company expects bigger vacation ...
Redeye increase our growth expectations for the long term while making minor adjustments for the nea...
Redeye strengthens its positive view of Avensia following a strong Q2 report, with growth and margin...
Redeye makes minor estimate revisions following Arise’s Q2 report, which was very much in line with ...
Redeye leaves an initial comment following the Q2 report published by Magle this morning.
Hansa’s Q2 sales confirm a period of continuing progress.
SRV's net sales in Q2 amounted to EUR 186.3m, slightly above our estimate of EUR 178.
Redeye was a bit surprised by the dip in gross margins in the second quarter.
- Sales and EBITDA in line with ABGSCe - Simplicity and predictability likely to drive limited cons.
Incap upgraded its 2024 full year guidance. Net sales is now guided to grow (previously decline) in ...
Redeye provides a short comment on Ortoma’s Q2 report this morning.
Redeye states that the Q2 report came in above its estimates on both sales and EBITDA.
- Sales -6% y-o-y, -12% vs. ABGSCe - EBIT of SEK 49m, +12% vs.
Redeye provides its initial take on ADDvise’s Q2 2024 report, which came in broadly below our estima...
- Net sales SEK 191m, 3% vs ABGSCe, 2% vs Factset cons.
Redeye retains its positive view on Lagercrantz following a Q1 report in-line with our estimates.
Svedbergs Group posted a solid set of Q2 2024 numbers, with sales coming in-line with our estimates ...
Redeye comments on the Q2 report released earlier this morning.
